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Concise Syntheses of Bridged Morpholines 
Andrey V. Zaytsev,a James E. Pickles,b Suzannah J. Harnor,b Alistair P. Henderson,a Mohammed 
Alyasiri,b Paul G. Waddell,c Celine Cano,b Roger J. Griffin,b , and Bernard T. Golding*a,b 
Concise and practical syntheses of 8-oxa-3-aza-bicyclo[3.2.1]octane and 9-oxa-3-aza-bicyclo[3.3.1]nonane are described 
starting from furan-2,5-dicarboxylic acid and 4H-pyran-2,6-dicarboxylic acid, respectively, and using a solvent-free step for 
a key cyclisation.
Introduction 
The morpholino unit is a privileged fragment1 in numerous 
drugs2 by virtue of its preferred chair conformation, oxygen 
lone pairs that can act as hydrogen bond acceptor(s) and a 
nitrogen atom that enables attachment to an aromatic or 
heteroaromatic scaffold. The importance of morpholino 
groups and especially their pseudoequatorial lone pair has 
recently been highlighted for inhibitors of phosphatidylinositol 
3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related 
protein kinases (PIKKs).3 The interaction of the morpholino 
group of an inhibitor with its target was described as 
‘representing a cornerstone in drug development of novel PI3K 
inhibitors’.3 To modulate the properties of a morpholino unit 
in such inhibitors, one or more of the methylene groups may 
be substituted, which has enabled selectivity to be achieved 
amongst members of the PI kinase families. Thus, selectivity 
for mTOR (the mammalian target of rapamycin) over PI3K, 
was attained by replacing a morpholino unit in certain 
pyrazolopyrimidines with the bridged morpholine 8-oxa-3-aza-
bicyclo[3.2.1]octane 1a.4 This morpholine analogue has also 
been used to introduce a bridged morpholino group into other 
compounds targeting mTOR,5 as well as inhibitors of Aurora 
kinases6 and glucokinase.7 Such modifications permit the 
properties of inhibitors to be modulated, e.g. cLogP is 
increased and a subtle structural feature is incorporated. For 
the mTOR pyrazolopyrimidine inhibitors with a bridged 
morpholine in place of the parent morpholine, hydrophobic 
interactions with the kinase’s critical ‘hinge’ region were 
enhanced.4 
Results and Discussion 
Owing to the current pharmaceutical interest in 
conformationally constrained (‘bridged’) morpholines, new 
synthetic methods to access these compounds have recently 
been developed.8-10 Two exemplars are the bridged 
morpholines 8-oxa-3-aza-bicyclo[3.2.1]octane 1a and 9-oxa-3-
aza-bicyclo[3.3.1]nonane 2a. The latter compound has only 
been described as N-substituted derivatives in patents.11 
Compared to 1a, morpholine 2a provides a significant increase 
in cLogP (~ 0.4) and the possibility of an enhanced interaction 
at a hydrophobic binding site of a target protein.  
The synthesis of 1a has been previously achieved by 
reducing 5-hydroxymethyl-2-furfural to 2,5-bis-hydroxymethyl-
tetrahydrofuran, the di-p-toluenesulfonate of which was 
treated with ammonia (under pressure at 170 oC) or 
benzylamine. These methods either afforded 1a directly in 
very low yield12-16 or in better yield (43-64%) via an 
intermediate N-benzyl compound, which was subjected to 
hydrogenolysis.17 The latter synthesis was scaleable, but 
required two high-pressure hydrogenations. 
We have developed an efficient and rapid synthesis of 8-
oxa-3-aza-bicyclo[3.2.1]octane 1a (Scheme 1) from furan-2,5-
dicarboxylic acid 3 via 4 and 5 that avoids high-pressure 
hydrogenation steps and is solvent-free for the key cyclisation 
step. The synthesis was inspired by Komppa’s classical route18 
to 3-aza-bicyclo[3.3.1]nonane 2b, whereby  cis-cyclohexane-
1,3-dicarboxylic acid 6b was neutralised with aqueous 
ammonia and the solution evaporated presumably to give 7b, 
which was heated at ~ 300 oC affording imide 8b. Compound 
8b was reduced to 2b, either electrolytically under strongly 
acidic conditions18 or with lithium aluminium hydride.19 This 
route to 2b was modified in the manner described below for 
1a, again starting from cis-cyclohexane-1,3-dicarboxylic acid 
and proceeding via 6b and 7b (see Scheme 2 and 
Supplementary Information).  
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Scheme 1: Reagents and Conditions i) Pd/C, H2, AcOH, 60 oC, 69 h, then aq. NH3, RT, 30 
min, 100%; ii) 230 oC (stirred solid), 6 h, 78%; iii) BH3 in THF, 67 oC, 2 h, then HCl in 
MeOH, 70 oC, 3 h, 70%; iv) BD3 in THF, 67 oC, 24 h; then HCl in MeOH, 70 oC, 3 h, 30%. 
The route to 1a parallels that for 2b and is convenient on a 
laboratory scale, as well as being applicable to the synthesis of 
other bridged morpholines exemplified here by an analogous 
synthesis of 2a. Catalytic hydrogenation of furan-2,5-
dicarboxylic acid 3 was performed at atmospheric pressure in 
acetic acid at 60 C to give (2R,5S)-tetrahydrofuran-2,5-
dicarboxylic acid 4, which was isolated as its crystalline di-
ammonium salt in almost quantitative yield. The configuration 
of 4 was assigned by analogy with that of compound 6a (see 
below). Thermolysis of the di-ammonium salt of 4 using either 
microwave or conventional heating gave 8-oxa-3-aza-
bicyclo[3.2.1]octane-2,4-dione 5 (Scheme 1). Optimisation of 
the reaction conditions enabled imide 5 to be prepared in up 
to 78% yield, using conventional heating of 4. A variety of 
solvents and conditions was explored for the conversion of 4 
into 5, but none provided a higher yield than heating at 230 oC 
the melt derived from the neat solid of 4. Finally, reduction of 
imide 5 with borane gave the desired bridged morpholine 1a, 
which was isolated as its hydrochloride in 70% yield. None of 
the steps in this sequence required chromatographic 
purification.  
In a similar manner (Scheme 2), the readily available 4H-
pyran-2,6-dicarboxylic acid20 was reduced (H2, cat. Pd/C) to 
(2R,6S)-tetrahydro-2H-pyran-2,6-dicarboxylic acid 6a, which 
was isolated as crystals of the di-ammonium salt 7a. The 
configuration of the diacid was previously assigned by Cope 
and Fournier20 and was confirmed by the crystal structure 
analysis (CCDC: 1471854; for data see Table 1, Supplementary 
Information) of the di-ammonium salt 7a, which showed a 
chair conformer with both carboxyl groups equatorial (Figure 
1). In this structure the protons of the acid groups have been 
modelled as disordered over two positions along the 
intermolecular hydrogen bond vectors in such a way that the 
structure with the highest occupancy is a co-crystal of both the 
deprotonated and doubly-protonated forms.  
Thermolysis of 7a gave 9-oxa-3-azabicyclo[3.3.1]nonane-2,4-dione 
8a, which was reduced with borane to afford 9-oxa-3-aza-
bicyclo[3.3.1]nonane 2a, isolated as its crystalline hydrochloride. A 
similar cyclisation of diammonium (2R,4s,6S)-4-(benzyloxy)-
tetrahydro-2H-pyran-2,6-dicarboxylate 7c gave (1R,5S,7s)-7-
(benzyloxy)-9-oxa-3-azabicyclo[3.3.1]nonane-2,4-dione 8c (see 
Supplementary Information for the synthesis of 6c). 
 
Scheme 2: Reagents and Conditions i) Aq. NH3, RT, 2 h, 98%; ii) 230 oC (stirred solid 
heated), 6 h, 76%; iii) BH3 in THF, 67 oC, 2.5 h, then HCl in Et2O, 70 oC, 3 h, 68%. 
 
Figure 1: The asymmetric unit of the crystal structure of 7a (di-ammonium salt).  Only 
the carboxylic acid protons with the highest occupancy are shown for clarity. Thermal 
ellipsoids are drawn at the 50% probability level. 
Conclusions 
Syntheses of 8-oxa-3-aza-bicyclo[3.2.1]octane 1a and 9-oxa-3-
aza-bicyclo[3.3.1]nonane 2a were each rapidly and simply 
achieved with an overall yield of 50-55% without any 
hazardous steps, laborious purifications or costly reagents. The 
key cyclisation step is solvent-free. The developed 
methodology was also used to prepare [2,2,4,4-2H4]8-oxa-3-
aza-bicyclo[3.2.1]octane 1b (Scheme 1), which is potentially 
useful for metabolic studies of drugs containing the bridged 
morpholine unit derived from 1a. The method described is 
versatile being applicable to both cycloalkane-1,3-
dicarboxylates18,19 and oxacycloalkane-1,3-dicarboxylates.  
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Supporting Information 
Experimental Section 
General Information 
1H, 2H and 13C nuclear magnetic resonance (NMR) spectra were obtained as solutions in a 
suitable deuterated solvent and recorded at 500 MHz, 76 MHz and 125 MHz, respectively, on 
a Bruker Avance III 500 spectrometer. Chemical shifts are reported in parts per million (δ) 
referenced to the deuterated solvent employed. Multiplicities are indicated by s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet), b (broad), hep (heptet) or combinations 
thereof. LCMS was carried out on a Waters Acquity SQD operating in positive and negative 
ion electrospray mode, employing a 50 × 2.1 mm, Waters Acquity UPLC BEH C18, 1.7 μm 
column and a 1.5 min gradient elution of 0.1% aqueous formic acid and acetonitrile (5–95%) 
at a flow rate of 0.6 mL min−1. High resolution mass spectrometry were measured using a 
Finnigan MAT 95 XP or a Finnigan MAT 900 XLT by the EPSRC National Mass 
Spectrometry Service Centre, University of Wales (Swansea), Singleton Park, Swansea, SA2 
8PP. Infrared (IR) spectra were recorded on a Bio-Rad FTS 3000MX diamond ATR as a neat 
sample. UV spectra were obtained using a U-2001 Hitachi Spectrophotometer with the 
sample dissolved in ethanol. All commercial reagents and solvents were purchased from 
reputable suppliers. Where petrol is stated, this refers to the fraction of alkanes, which boils 
between 40 oC and 60 oC. The chemicals were of the highest available purity and used as 
supplied unless otherwise stated. Anhydrous solvents were stored under nitrogen. Reactions 
requiring microwave irradiation were carried out in a Biotage Initiator™ Sixty reactor. 
General procedure A 
10% Pd/C (~ 10 wt%) was added to the carboxylic acid (for typical scale see below) 
dissolved in AcOH (1.5 mL/mmol). Following evacuation, an atmosphere of hydrogen was 
introduced via a balloon. After stirring vigorously for 69 h at 60 oC, the suspension was 
filtered through a Celite plug, eluting with AcOH (1.5 mL/mmol). The solvent was removed 
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in vacuo and the resultant solid was dissolved in water (0.6 mL/mmol) before the addition of 
35% ammonium hydroxide in water (0.6 mL/mmol). The mixture was stirred at RT for 30 
min after which it was concentrated and dried in vacuo to afford the product. 
General procedure B 
A reaction vessel was equipped with a stirrer bar, finely powdered diammonium salt (for 
typical scale see below and covered with glass wool. The mixture was stirred and heated at 
230 oC for 6 h. EtOAc (10 mL/mmol) was added along with sat. sodium bicarbonate solution 
(10 mL/mmol) and the mixture was sonicated to dissolve all the solids. The aqueous layer 
was extracted twice with EtOAc and the collated organic layers were dried (MgSO4) and 
evaporated to dryness. 
General procedure C 
Under an inert atmosphere, to the imide (for typical scale see below) in anhydrous THF (2.3 
mL/mmol) was added 1 M BH3-THF solution (4 mmol per mmol substrate) was added 
cautiously and the reaction mixture was heated at reflux for 3 h. After cooling to RT, the 
reaction was quenched MeOH until effervescence ceased, evaporated to dryness and taken up 
in MeOH (1.7 mL/mmol). A 1.25 M solution of hydrogen chloride in MeOH (1.7 mL/mmol) 
was added and, under nitrogen, the solution was heated at reflux for 3 h. After cooling to RT, 
the solvent was removed in vacuo and the crude product was purified by recrystallisation 
from MeOH-diethyl ether.  
Diammonium tetrahydrofuran-2,5-dicarboxylate 4:  
 
 
 
Prepared according to general procedure A with the following reagents: 2,5-
furandicarboxylic acid (3, 5.00 g, 32.0 mmol), Pd/C (510 mg), AcOH (50 mL), water (20 
mL) and 35% ammonium hydroxide in water (20 mL) affording 4 as a white solid (6.06 g, 
32.0 mmol, 100%); Rf = 0.51 (DCM:MeOH, 90:10); m.p: 227–230 oC; IR νmax/cm-1 3178, 
2993, 2869, 2778, 1699, 1545; 1H NMR (500 MHz, D2O) δ 1.73–1.79 (2H, m, 2  CH), 
2.13–2.20 (2H, m, 2  CH), 4.10–4.16 (2H, m, 2  CH); 13C NMR (125 MHz, D2O) δ 30.1, 
79.7, 180.4); HRMS calcd. for C6H6O5 m/z [M+H]
+ 159.0296, found 159.0299. 
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8-Oxa-3-azabicyclo[3.2.1]octane-2,4-dione 5: 
 
 
 
 
Prepared according to general procedure B starting from 4 (200 mg, 1.03 mmol), which gave 
5 as a white solid (110 mg, 0.80 mmol, 78%). Rf = 0.60 (EtOAc); mp: 133–137 oC; IR 
νmax/cm-1 3082, 2839, 1907, 1713; 1H NMR (500 MHz, DMSO-d6) δ 1.92–1.97 (2H, m, 2  
CH), 2.13–2.21 (2H, m, 2  CH), 4.70–4.74 (2H, m, 2  CH), 11.10 (1H, br s, NH); 13C NMR 
(125 MHz, DMSO-d6) δ 30.1, 79.7, 180.4; HRMS calcd. for C6H7NO3 m/z [M+H]+ 142.0499, 
found 142.0496. 
8-Oxa-3-azabicyclo[3.2.1]octane hydrochloride 1a: 
 
 
 
 
 
Prepared according to general procedure C with the following reagents: 5 (306 mg, 2.17 
mmol), THF (5 mL), 1 M BH3-THF solution (8.7 mL, 8.7 mmol), MeOH (5 mL), 1.25 M 
solution of hydrogen chloride in MeOH (6 mL) affording 1a as an off white solid (0.227 g, 
1.52 mmol, 70%); Rf = 0.93 (EtOAc); mp: 192–195 oC; IR νmax/cm-1 2958, 2899, 2845, 2768, 
2660, 2548, 2492, 2360, 2293, 1598; 1H NMR (500 MHz, DMSO-d6) δ 1.91-1.98 (2H, m, 2  
CH), 2.03-2.09 (2H, m, 2  CH), 2.95-3.06 (4H, m, 4  CH), 4.37-4.41 (2H, m, 2  CH), 
8.93-9.37 (2H, m, NH2); 
13C NMR (125 MHz, DMSO-d6) δ 26.6, 47.1, 71.6; HRMS calcd. 
for C6H11NO m/z [M+H]
+ 114.0912, found 114.0913. 
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8-Oxa-3-azabicyclo[3.2.1]octan-3-ium-2,2,4,4-d4 chloride 1b: 
 
Prepared according to general procedure C with the following reagents: 5 (345 mg, 2.45 
mmol), THF (5.6 mL), 1 M BD3-THF solution (9.79 mL, 9.79 mmol), MeOH (5.6 mL), 1.25 
M HCl in MeOH (5.6 mL) yielding 1b as an off-white solid (113 mg, 0.96 mmol, 30%); Rf = 
0.21 (DCM:MeOH, 80:20); mp: 192-198 oC; 1H NMR (500 MHz, DMSO-d6) δ 1.90-1.97 
(2H, m, 2  CH), 2.04-2.10 (2H, m, 2  CH), 2.95-3.05 (0.76H,m , non-deuterated material), 
4.37-4.41 (2H, m, 2  CH), 9.38 (2H, br s, NH2); 13C NMR (125 MHz, DMSO-d6) δ 27.3 
(CH2), 46.3-47.5 (1:2:3:2:1 pent, 2 x CD2), 72.0 (CH); HRMS calcd. for C6H7D4NO m/z 
[M+H]+ 118.1164, found 118.1161. 
4H-Pyran-2,6-dicarboxylic acid1,2 
 
To a stirred solution of tetraethyl 1,5-dioxopentane-1,2,4,5-tetracarboxylate (1.59 g, 4.10 
mmol) in water (1.6 mL) was added concentrated hydrochloric acid (1.6 mL). The mixture 
was heated at reflux for 6 h, after which the solvent was removed in vacuo. To the stirred 
residue was added conc. sulfuric acid (2 mL) dropwise. The mixture was cooled to 0 oC and 
stirred for 18 h. Ice-cold water was added to give a precipitate which was filtered, washed 
with ice cold water (3 × 10 mL) and dried to give a brown solid. According to 1H NMR 
analysis this product was a mixture of the title compound and ethyl ester(s). The mixture was 
taken up in THF (25 mL) and 2M aqueous NaOH (22.5 mL) was added. After stirring at 
room temperature overnight, the resulting solution was acidified with 2M HCl. The 
precipitate was filtered, washed with ice-cold water and dried to afford the title compound as 
a brown solid (0.50 g, 2.9 mmol, 71%). Rf = 0.15 (DCM:MeOH, 95:5); mp = 250
 oC dec; 
λmax (EtOH/nm) 234; IR (neat) νmax/cm-1 3420, 3014, 2845, 1724, 1632; 1H NMR (500 MHz, 
DMSO-d6) δ 3.02 (2H, t, J = 3.7 Hz, CH2), 6.01 (2H, t, J = 3.7 Hz), 13.1 (2H, br s, 2 × 
OH); 13C NMR (125 MHz, DMSO-d6) δ 21.6 (CH2), 110.2 (CH), 142.2 (CH), 162.2 (C=O); 
HRMS calcd. for C7H6O5 m/z [M+H]
+ 171.0288, found 171.0288. 
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Ammonium (2R,6S)-tetrahydro-2H-pyran-2,6-dicarboxylate 6a: 
 
Prepared according to general procedure A with the following reagents: 4H-pyran-2,6-
dicarboxylic acid (3.47 g, 20.5 mmol), AcOH (70 mL), Pd/C (326 mg), water (35 mL) and 
35% ammonium hydroxide solution (6.3 mL). Compound 6a was an off-white solid (4.16 g, 
20 mmol, 98%). Rf = 0.41 (DCM:MeOH, 60:40); mp: 212-220 
oC; IR νmax/cm-1 2921, 2851, 
1561, 1403; 1H NMR (500 MHz, DMSO-d6) δ 1.24-1.37 (2H, m, 2  CH), 1.49-1.62 (1H, m, 
CH), 1.76-1.93 (3H, m, 3  CH), 3.66 (2H, dd, J = 2.2 and 10.9 Hz, 2  CH), 7.90 (8H, br s, 
2  NH4); 13C NMR (125 MHz, DMSO-d6) δ 23.9, 29.3, 77.9, 175.1; HRMS calcd. for 
C7H10O5 m/z [M+H]
+ 173.0455, found 173.0459. 
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9-Oxa-3-azabicyclo[3.3.1]nonane-2,4-dione 7a: 
 
Prepared according to general procedure B starting from 6a (150 mg, 0.72 mmol) furnishing 
7a as a white solid (85 mg, 0.55 mmol, 76%). Rf = 0.29 (petrol:EtOAc, 60:40); mp: 149-157 
oC; IR νmax/cm-1 3077, 2958, 2925, 2852, 1702; 1H NMR (500 MHz, DMSO-d6) δ 1.35-1.50 
(1H, m, CH), 1.66-1.77 (3H, m, 3  CH), 1.84-1.94 (2H, m, 2  CH), 4.45 (2H, dd, J = 1.0 
and 5.4 Hz, 2  CH), 11.58 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 16.6, 26.0, 
71.3, 173.7; HRMS calcd. for C7H9NO3 m/z [M+H]
+ 156.0655, found 156.0653. 
9-Oxa-3-azabicyclo[3.3.1]nonane hydrochloride 2a: 
 
Prepared according to general procedure C with the following reagents: 7a (585 mg, 3.77 
mmol), THF (5 mL), 1 M BH3-THF (15.1 mL, 15.1 mmol), MeOH (15 mL) and 1 M HCl in 
Et2O (30 mL), furnishing 2a as a white solid (420 mg, 2.56 mmol, 68%). Rf = 0.16 
(DCM:MeOH, 80:20); mp: 242-250 oC; IR νmax/cm-1 3092, 2753, 2637, 2494, 1591; 1H NMR 
(500 MHz, DMSO-d6) δ 1.56-1.69 (3H, m, 3  CH), 1.89 (2H, heptet, 2  CH), 2.00-2.16 
(1H, m, CH), 3.19-3.22 (4H, m, 2  CH2), 4.03 (2H, br s, 2  CH), 8.28 (1H, br s, NH), 9.72 
(1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 16.7, 27.7, 44.4, 63.8; HRMS calcd. for 
C7H13NO m/z [M+H]
+ 128.1070, found 128.1067. 
Ammonium (1R,3S)-cyclohexane-1,3-dicarboxylate 6b: 
 
Prepared according to general procedure A with the following reagents: (1R,3S)-cyclohexane-
1,3-dicarboxylic acid (2.5 g, 14.5 mmol) in water (10 mL) with 35% ammonium hydroxide in 
water (10 mL). Compound 6b was a white solid (3.0 g, 14.5 mmol, 100%). Rf = 0.31 
(DCM:MeOH, 90:10); mp: 127-134 oC; IR νmax/cm-1 2922, 1686; 1H NMR (500 MHz, 
DMSO-d6) δ 1.14-1.35 (4H, m, 4  CH), 1.74-1.90 (3H, m, 3  CH), 2.00-2.15 (3H, m, 3  
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CH), 5.97 (8H, br s, 2  NH4); 13C NMR (125 MHz, DMSO-d6) δ 25.5 (CH2), 29.7 (CH2), 
33.1, 44.2, 178.1; HRMS calcd. for C8H10O4 m/z [M+H]
+ 171.0663, found 171.0667. 
3-Azabicyclo[3.3.1]nonane-2,4-dione 7b: 
 
Prepared according to general procedure B from compound 6b (950 mg, 4.61 mmol). 7b was 
a white solid (489 mg, 3.20 mmol, 69%). Rf = 0.63 (DCM:MeOH, 90:10); mp: 123-130 
oC; 
IR νmax/cm-1 2952, 2925, 1696; 1H NMR (500 MHz, CDCl3) δ 1.40-1.51 (2H, m, 2  CH), 
1.60-1.75 (3H, m, 3  CH), 1.92-1.99 (2H, m, 2  CH), 2.13-2.20 (1H, m, CH), 7.73-7.78 
(2H, m, 2  CH), 7.84 (1H, br s, NH); 13C NMR (125 MHz, CDCl3) δ 19.4, 27.9, 28.9, 37.7, 
175.8; HRMS calcd. for C8H11NO2 m/z [M+H]
+ 154.0863, found 154.0859. 
3-Azabicyclo[3.3.1]nonane hydrochloride 2b 
 
Prepared according to general procedure C with the following reagents: Compound 7b (289 
mg, 1.80 mmol), THF (3 mL), 1 M BH3-THF (7.5 mL, 7.5 mmol), MeOH (10 mL) and 1 M 
HCl in MeOH (10 mL) furnishing 2b as a white solid (200 mg, 1.23 mmol, 69%). Rf = 0.13 
(MeOH); mp: 209-214 oC; IR νmax/cm-1 2924, 2674, 1587, 1445; 1H NMR (500 MHz, CDCl3) 
δ 1.50-1.79 (8H, m, 8  CH), 1.86-2.00 (2H, m, 2  CH), 3.03-3.12 (2H, m, 2  CH), 3.17-
3.23 (2H, m, 2  CH), 7.67 (1H, br s, NH), 9.29 (1H, br s, NH); 13C NMR (125 MHz, CDCl3) 
δ 19.9, 25.7, 29.2, 30.2, 47.3; HRMS calcd. for C8H16N m/z [M+H]+ 126.1277, found 
126.1277. 
 
 
 
Synthesis of (1R,5S,7s)-7-(benzyloxy)-9-oxa-3-azabicyclo[3.3.1]nonane-2,4-dione 8c: 
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Reagents and Conditions: i) H2SO4, EtOH, RT, 48 h, 70%; ii) H2, Pd/BaSO4, EtOH, RT, 20 
h, 67%; iii) BnOC(NH)CCl3, TfOH, DCM:cyclohexane, RT, 24 h, 91%; iv) LiOH, THF, RT, 
20 h, 100%; v) NH4OH, H2O, RT, 100%; vi) 230 
oC, 6 h, 37%. 
Diethyl 4-oxo-4H-pyran-2,6-dicarboxylate 
 
To a solution of 4-oxo-4H-pyran-2,6-dicarboxylic acid (1.54 g, 7.61 mmol) in ethanol (30 
mL) at 0 oC was added conc. sulfuric acid (1.2 mL) dropwise over 5 min. The mixture was 
warmed to room temperature and then heated at reflux for 48 h. After cooling to RT, the 
solvent was removed in vacuo and the residue taken up into ethyl acetate (5 mL). Saturated 
sodium hydrogen carbonate was added until the aqueous layer pH was ~ 7. The aqueous layer 
was extracted with EtOAc (3 × 20 mL); the organic extracts were combined, dried over 
anhydrous MgSO4 and the solvent was removed in vacuo to afford the title compound as an 
orange oil which was used directly (1.25 g, 5.2 mmol, 70%); Rf = 0.44 (Petrol:EtOAc, 1:1); 
λmax (EtOH/nm) 271; IR νmax/cm-1 3071, 2984, 1650; 1H NMR (500 MHz, CDCl3) δ  1.40 
(6H, t, J = 7.1 Hz, 2 × CH3), 4.44 (4H, q, J = 7.1 Hz, 2 × CH2), 7.10 (2H, s, 2 × CH); 
13C-
NMR (125 MHz, CDCl3) δ 14.0, 63.2, 120.1, 153.0, 159.4, 177.1; HRMS calcd. for C11H12O6 
m/z [M+H]+ 241.0707, found 241.0705. 
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Diethyl (2R,4s,6S)-4-hydroxytetrahydro-2H-pyran-2,6-dicarboxylate 
 
To diethyl 4-oxo-4H-pyran-2,6-dicarboxylate (1.4 g, 5.82 mmol) in ethanol (20 mL) was 
added a catalytic quantity of Pd/BaSO4 and the mixture was placed under an atmosphere of 
hydrogen. After stirring for 20 h, the slurry was filtered through a pad of Celite, which was 
washed with ethanol (20 mL); the solvent was removed in vacuo. The crude product was 
purified by column chromatography (silica, elution with petrol:EtOAc, 1:1) to give the title 
compound as a colourless oil (0.98 g, 3.79 mmol, 67%); Rf = 0.17 (PE:EA 1:1); IR νmax/cm-1 
3497, 3339, 2983, 1719;  1H NMR (500 MHz, CDCl3) δ 1.28 (6H, t, J = 7.1 Hz, 2 × CH3), 
1.54 (2H, q, J = 12.0 Hz, 2 × CH2), 2.22 -2.32 (2H, m, 2 × CH2), 2.39 (1H, br s, OH), 3.95 
(1H, tt, J = 4.5 and 10.9 Hz, CH), 4.01 (2H, dd,  J = 2.0 and 12.0 Hz, 2 × CH2), 4.22 ( 4H, q, 
J = 7.1 Hz, 2 × CH2); 
13C NMR (125 MHz, CDCl3) δ 14.1, 37.2, 61.5, 67.2, 74.8, 169.7; 
HRMS calcd. for C11H18O6 m/z [M+H]
+ 247.1176, found 247.1179. 
 
Diethyl (2R,4s,6S)-4-(benzyloxy)tetrahydro-2H-pyran-2,6-dicarboxylate3  
 
Diethyl (2R,4s,6S)-4-hydroxytetrahydro-2H-pyran-2,6-dicarboxylate (1.3 g, 5.3 mmol) was 
dissolved in DCM (11 mL) and cyclohexane (11 mL). Benzyl trichloroacetamidate (1.09 mL, 
5.83 mmol) was introduced dropwise followed by TFA (56 µL) in DCM (0.5 mL). After 15 
h, more benzyl trichloroacetamidate (0.55 mL, 2.92 mmol) was added with TFA (38 µL) in 
DCM (0.5 mL). After a further 4 h at RT, the solvent was removed in vacuo and the crude 
product was purified by MPLC (elution with petrol:EtOAc, 70:30) affording the title 
compound as a colourless oil (1.6 g, 4.8 mmol, 91%); Rf = 0.53 (petrol:EtOAc, 1:1); IR 
(neat) νmax/cm-1 1734; 1H NMR (500 MHz, CDCl3) δ 1.23 (6H, t, J = 7.2 Hz, 2 × CH3), 1.55 
(2H, q, J = 12.2 Hz, 2 × CH), 2.32-2.39 (2H, m, 2 × CH), 3.61 (1H, tt, J = 4.4 Hz and 10.9 
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Hz, CH), 4.18 (4H, q, J = 7.2 Hz, 2 × CH2), 4.54 (2H, s, CH2), 7.20-7.32 (5H, m, 5 × H-Ar); 
13C NMR (125 MHz, CDCl3) δ 14.3, 34.6, 61.6, 69.9, 73.4, 75.0, 127.6, 127.9, 128.6, 138.0, 
169.7; HRMS calcd. for C18H24O6 m/z [M+H]
+ 354.1911, found 354.1915. 
 
(2R,4s,6S)-4-(Benzyloxy)tetrahydro-2H-pyran-2,6-dicarboxylic acid 6c: 
 
To diethyl (2R,4s,6S)-4-(benzyloxy)tetrahydro-2H-pyran-2,6-dicarboxylate (218 mg, 0.60 
mmol) in THF (6.5 mL) was added 2 M LiOH in water (4.5 mL, 8.9 mmol) and the mixture 
was stirred at room temperature for 28 h. The solvent was removed in vacuo and the residue 
taken up in EtOAc (5 mL), H2O (2 mL) was added and the pH of the aqueous layer was 
adjusted to 2 with 2M HCl. The product was extracted with EtOAc (3  15 mL), the organic 
extracts were combined and dried (MgSO4), and the solvent was removed in vacuo to afford 
the title compound as a white solid (180 mg, 0.64 mmol, 100%.); Rf = 0.27 (DCM:MeOH, 
50:50); mp 165-172 oC; IR (neat) νmax/cm-1 3247, 1765, 1711; 1H NMR (500 MHz, DMSO-
d6) δ 1.30 (2H, q, J = 12.2 Hz, 2 × CH), 2.25-2.30 (2H, m, 2 × CH), 3.74 (1H, tt, J = 4.4 Hz 
and 10.9 Hz, CH), 4.02 (2H, dd, J = 1.9 and 12.3 Hz, 2 × CH), 4.57 (2H, s, CH2), 7.25-7.40 
(5H, m, 5 × H-Ar), 12.75 (2H, br s, OH); 13C NMR (125 MHz, DMSO-d6) δ 39.9, 69.3, 73.4, 
74.0, 127.8, 127.9, 128.7, 139.2, 171.7; HRMS calcd. for C14H16O6 m/z [M-H]
- 279.0874, 
found 279.0876. 
 
Diammonium (2R,4s,6S)-4-(benzyloxy)tetrahydro-2H-pyran-2,6-dicarboxylate 7c: 
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(2R,4s,6S)-4-(Benzyloxy)tetrahydro-2H-pyran-2,6-dicarboxylic acid (700 mg, 2.5 mmol) was 
solubilised in water (3.5 mL) and 35% ammonium hydroxide in water (3.5 mL) was added 
dropwise. After stirring for 3 h at RT, the solvent was removed in vacuo and by freeze 
drying, to afford the title compound as a white solid (750 mg, 2.5 mmol, 100%.); Rf = 0.37 
(DCM:MeOH, 50:50); mp 234-238 oC; IR (neat) νmax/cm-1 3199, 1574; 1H NMR (500 MHz, 
DMSO-d6) δ 1.14 (2H, q, J = 11.8 Hz, 2 × CH), 2.31-2.37 (2H, m, 2 × CH), 3.51-3.63 (3H, 
m, CH and 2 × CH), 4.59 (2H, s, CH2), 7.20-7.44 (5H, m, 5 × H-Ar), 7.82 (8H, br s, NH); 
13C 
NMR (125 MHz, DMSO-d6) δ 36.5, 69.0, 75.6, 76.4, 127.7, 127.8, 128.7, 139.6, 175.1; 
HRMS calcd. for C14H22N2O6 m/z 279.0874 [M-H]
-, found 279.0876. 
 
(1R,5S,7s)-7-(benzyloxy)-9-oxa-3-azabicyclo[3.3.1]nonane-2,4-dione 8c: 
 
(1R,5S,7s)-7-(benzyloxy)-9-oxa-3-azabicyclo[3.3.1]nonane-2,4-dione was synthesised 
according to general procedure B, using: diammonium (2R,4s,6S)-4-(benzyloxy)tetrahydro-
2H-pyran-2,6-dicarboxylate (300 mg, 0.90 mmol) and purification by MPLC (petrol:EtOAc, 
70:30) to afford the title compound as a white solid (83 mg, 0.32 mmol, 35%); Rf = 0.57 
(EtOAc); mp 164-169 oC; IR (neat) νmax/cm-1 3178, 1698; 1H NMR (500 MHz, CDCl3) 2.07 
(2H, dq, J = 3.3 and 14.5 Hz, 2 x CH), 2.21-2.34 (2H, m, 2  CH), 3.78 (1H, pen, J = 2.7 Hz, 
CH), 4.33 (2H, s, CH2), 4.41 (2H, d, J = 6.1 Hz, 2  CH), 7.12-7.30 (5H, m, 5  H-Ar), 7.87 
(1H, bs, NH); 13C NMR (125 MHz, CDCl3) δ 29.9, 68.6, 69.4, 70.0, 126.3, 126.7, 127.4, 
136.3, 171.6; HRMS calcd. for C14H15NO4 m/z 279.1339 [M+H]
+, found 279.1344. 
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Table 1: Crystal data and structure refinement for 6a.  
Empirical formula  C7H13NO5  
Formula weight  191.18  
Temperature/K  150.0(2)  
Crystal system  triclinic  
Space group  P-1  
a/Å  6.9141(2)  
b/Å  9.3897(3)  
c/Å  14.4781(5)  
α/°  101.468(3)  
β/°  96.993(3)  
γ/°  98.349(3)  
Volume/Å3  900.34(5)  
Z  4  
ρcalcg/cm3  1.410  
μ/mm-1  1.036  
F(000)  408.0  
Crystal size/mm3  0.15 × 0.11 × 0.08  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  6.306 to 133.746  
Index ranges  -8 ≤ h ≤ 8, -11 ≤ k ≤ 11, -16 ≤ l ≤ 14  
Reflections collected  12629  
Independent reflections  3184 [Rint = 0.0253, Rsigma = 0.0180]  
Data/restraints/parameters  3184/2/275  
Goodness-of-fit on F2  1.038  
Final R indexes [I>=2σ (I)]  R1 = 0.0312, wR2 = 0.0817  
Final R indexes [all data]  R1 = 0.0345, wR2 = 0.0843  
Largest diff. peak/hole / e Å-3  0.26/-0.24  
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